CSF2 and myeloid sarcoma: In fact, efficacious treatment with the disease-modifying agent interferon beta significantly decreases the number of GM-CSF-producing CD4+ T cells in the peripheral blood and in the CSF of patients with MS compared to untreated patients [59].